olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Essential Hypertension
Conditions
Essential Hypertension
Trial Timeline
Aug 1, 2006 → Aug 1, 2007
NCT ID
NCT00890591About olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary is a approved stage product being developed by Daiichi Sankyo for Essential Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT00890591. Target conditions include Essential Hypertension.
What happened to similar drugs?
14 of 20 similar drugs in Essential Hypertension were approved
Approved (14) Terminated (2) Active (6)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00890591 | Approved | Completed |
| NCT00311155 | Approved | Completed |
Competing Products
20 competing products in Essential Hypertension